Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
2(11%)
Results Posted
10%(1 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_2
4
22%
Ph phase_4
1
6%
Ph not_applicable
3
17%
Ph phase_3
5
28%
Ph phase_1
3
17%

Phase Distribution

3

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
5(31.3%)
Phase 4Post-market surveillance
1(6.3%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

2

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(10)
Terminated(3)
Other(3)

Detailed Status

Completed10
unknown2
Recruiting2
Withdrawn2
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
2
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (18.8%)
Phase 24 (25.0%)
Phase 35 (31.3%)
Phase 41 (6.3%)
N/A3 (18.8%)

Trials by Status

unknown211%
recruiting211%
suspended16%
withdrawn211%
terminated16%
completed1056%

Recent Activity

2 active trials
Showing 5 of 18
completedphase_4

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

NCT05491356
suspended

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
recruitingphase_2

Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)

NCT05766124
completedphase_3

Adjunctive, Low-dose tPA in Primary PCI for STEMI

NCT03335839
recruitingnot_applicable

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

NCT05736757
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05491356Phase 4

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Completed
NCT06310018

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

Suspended
NCT05766124Phase 2

Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)

Recruiting
NCT03335839Phase 3

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Completed
NCT05736757Not Applicable

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

Recruiting
NCT04453371Phase 3

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Withdrawn
NCT02752256

Thrombolytic Care During Inter-hospital Transfer

Completed
NCT01581411Phase 1

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Completed
NCT02388061Phase 2

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Completed
NCT03392792Not Applicable

Regisry of the Stroke Patients in Assiut University Hospital

Unknown
NCT00000505Phase 3

Thrombolysis in Myocardial Infarction (TIMI)

Completed
NCT00000472Phase 3

Thrombolysis in Myocardial Ischemia Trial (TIMI III)

Completed
NCT00000468Phase 3

Myocardial Infarction Triage and Intervention Project (MITI)

Completed
NCT01878136Phase 1

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

Withdrawn
NCT00417768Phase 2

Safety and Effectiveness of tPA in Intra-abdominal Abscesses

Terminated
NCT01451320Not Applicable

Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

Completed
NCT00283088Phase 1

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

Completed
NCT01098890Phase 2

Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18